A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
Status:
RECRUITING
Trial end date:
2041-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.